Design, synthesis and biological evaluation of novel 5-(imidazolyl-methyl) thiazolidinediones as antidiabetic agents

Bioorg Chem. 2021 Jul 13;115:105162. doi: 10.1016/j.bioorg.2021.105162. Online ahead of print.ABSTRACTA newly designed series of imidazolyl-methyl- l-2,4-thiazolidinediones 9 (a-m) were synthesized and In Silico studies were carried out to rationalize their anti-diabetic activity. Generally, all newly synthesized thiazolidinediones had anti-hyperglycemic activity compared with a diabetic-control group, without toxicity in 3T3 cells (viability ≥ 90%). These studies revealed that the compounds 9e and 9b (11∗10-6mol/kg) lowered blood glucose more effectively when compared to pioglitazone at the same dose. Following the administration of compound 9e, no weight gains or any serious side effects on liver and pancreas were observed. Moreover, the glucose consumption assay results showed a significant glucose-lowering effect (p < 0.001) in HepG2 cells, which were exposed to 11 mM of glucose at concentrations of 1.25-10 mM of compound 9e. Also, the PPAR-γ gene expression study revealed that pioglitazone and 9e showed similar behavior relative to the control group.PMID:34314919 | DOI:10.1016/j.bioorg.2021.105162

Source: Bioorganic Chemistry - July 27, 2021 Category: Chemistry Authors: Neda Shakour Amirhossein Sahebkar Gholamreza Karimi Maryam Paseban Aida Tasbandi Fatemeh Mosaffa Zahra Tayarani-Najaran Razieh Ghodsi Farzin Hadizadeh Source Type: research